Abstract: Described herein are solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof, and use of solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol in treating numerous diseases and disorders, including hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions, and neurodegenerative conditions in subjects or human patients.

Abstract: Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Abstract: A device for providing a skin or wound dressing, a wound treatment set, and a method to provide a skin or wound dressing, wherein the skin or wound dressing includes an active substance, and wherein the device comprises at least two chambers for the storage of at least two liquids, which are openable by mechanical action, so that, after opening of the chambers, the liquids are miscible and are transferrable to an active substance carrier.

Abstract: The invention relates to a method for the hydrometallurgical recovery of lithium from the lithium manganese oxide-containing fraction of used galvanic cells.

Abstract: Described herein are solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof, and use of solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol in treating numerous diseases and disorders, including hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions, and neurodegenerative conditions in subjects or human patients.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms. Cocrystals of cannabidiol and a coformer selected from L-proline, D-proline, tetramethylpyrazine, and 4,4?-dipyridyl are also disclosed herein.

Abstract: Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms.

Abstract: Method and apparatus are disclosed for remote keyless entry authentication. An example remote keyless entry system includes a key fob and a vehicle. The key fob generates a secured message with a plaintext space and a ciphertext space. The vehicle (i) determines whether the key fob may be authorized based on first information in the plaintext space, (ii) decrypts an encrypted value in the ciphertext space based on a predicted full counter value, and (iii) determines whether the key fob is authorized based on second information in the encrypted value.

Abstract: Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Abstract: Described herein are solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof, and use of solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol in treating numerous diseases and disorders, including hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions, and neurodegenerative conditions in subjects or human patients.

Abstract: Method and apparatus are disclosed for remote keyless entry authentication. An example remote keyless entry system includes a key fob and a vehicle. The key fob generates a secured message with a plaintext space and a ciphertext space. The vehicle (i) determines whether the key fob may be authorized based on first information in the plaintext space, (ii) decrypts an encrypted value in the ciphertext space based on a predicted full counter value, and (iii) determines whether the key fob is authorized based on second information in the encrypted value.

Abstract: A vehicle includes: receiver(s), a timer counting time, memory, and processor(s) configured to: receive a timestamped signal from a fob; compare the timestamp to a time window; reject the timestamp if the timestamp is outside the time window; expand the time window with the counted time; compute the time window as a trigonometric function of the counted time and a predetermined angle.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?, 7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?, 7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?, 7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: A vehicle includes: receiver(s), a timer counting time, memory, and processor(s) configured to: receive a timestamped signal from a fob; compare the timestamp to a time window; reject the timestamp if the timestamp is outside the time window; expand the time window with the counted time; compute the time window as a trigonometric function of the counted time and a predetermined angle.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: The invention relates to a process for coating metal surfaces with an aqueous composition in the form of a solution or in the form of a dispersion, the composition comprising at least one phosphate, at least 3 g/l of at least one titanium or/and zirconium compound and at least one complexing agent, and also to corresponding aqueous compositions.

Abstract: A method for the hydrometallurgical recovery of lithium from a lithium transition metal oxide containing fraction of used galvanic cells is disclosed. According to the method, the lithium transition metal oxide containing fraction is introduced into sulphuric acid or hydrochloric acid, and hydrogen peroxide is added in an amount that is at least stoichiometric relative to the transition metal content to be reduced of the lithium transition metal oxide-containing fraction.

Abstract: A method for the hydrometallurgical recovery of lithium from the fraction of used galvanic cells containing lithium, iron and phosphate is disclosed. According to the method, lithium-iron-phosphate-containing fraction is introduced into sulfuric acid and/or hydrochloric acid, and hydrogen peroxide is added in an amount that is at least stoichiometric relative to the iron content to be oxidized of the lithium-iron-phosphate-containing fraction.